Perspectives From Patients and Gastroenterologists on De-escalating Therapy for Crohn's Disease

Clin Gastroenterol Hepatol. 2021 Feb;19(2):403-405. doi: 10.1016/j.cgh.2019.11.062. Epub 2019 Dec 27.

Abstract

In Crohn's disease, combination therapy with anti-tumor necrosis factor (anti-TNF) agents and azathioprine/mercaptopurine has been shown to be superior to monotherapy with one of these treatments alone.1 This combination has its best success rate when used early in the course of treatment.2 However, because of the significant cost of these drugs and concerns over long-term side effects,3,4 many patients and providers often ask about stopping one or both of these medications.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Azathioprine / adverse effects
  • Crohn Disease* / drug therapy
  • Gastroenterologists*
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Infliximab / adverse effects
  • Mercaptopurine
  • Tumor Necrosis Factor Inhibitors

Substances

  • Immunosuppressive Agents
  • Tumor Necrosis Factor Inhibitors
  • Infliximab
  • Mercaptopurine
  • Azathioprine